News for Healthier Living

Key International Mpox Trial Finds No Clinical Benefit from Tecovirimat

William A. Fischer II, MD, Director of Emerging Pathogens at UNC's Institute for Global Health and Infectious Diseases and Joe Eron, MD, UNC Chief of Infectious Diseases and chair of the ACTG, co-authored a study that found tecovirimat used to treat mpox does not shorten time to lesion resolution, reduce pain, or speed viral clearance in adults. Published today in the New England Journal of Medicine, the results call for a renewed focus on new antivirals and combination strategies.

February 27, 2026


February 27 2026

February 26 2026

February 25 2026

February 24 2026

February 23 2026

February 22 2026

February 21 2026

February 20 2026

February 19 2026

February 18 2026

February 17 2026

February 16 2026

February 15 2026

February 14 2026